There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple options to appropriately treat and manage CAT, thrombosis is a complication that HCPs are not recognizing early enough; plus, there is a lack of awareness of new CAT management clinical data. While the morbidity and mortality of VTE in patients with cancer remain high, unfortunately, the management of it does not take the same priority. While recommendations suggest an individualized approach to managing these patients, adoption into clinical practice lags. Published guidelines and clinical trial data do not necessarily align with real-world practice and prescribing behaviors. As a result, many existing protocols for CAT management require updates, as new guidance is warranted. This program focuses on managing cancer-associated venous thromboembolic disease, with a special emphasis on translating real-world data and evidence-based medicine, including recent clinical guidelines, into clinical practice.
Treatment of Patients With Established VTE With Cancer and COVID-19
Treatment of Patients With Established VTE With Cancer and COVID-19
Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
Hi, my name is Alok Khorana, and I'm a Medical Oncologist and Director of the GI Cancer Program at the Cleveland Clinic in Cleveland, Ohio. And today I will be discussing the Treatment of Patients with Established VTE with Cancer and COVID-19.
As background, people with cancer are at higher risk for COVID-19 and its complications, including thromboembolism, severe disease, and mortality. The inflammatory response to SARS-CoV-2 infection can cause an acute - both and acute phase response and endothelial cell dysfunction. And together, this contributes to COVID-19-associated coagulopathy on a background of a hypercoagulable state of cancer in the first place.
D-dimer and other inflammatory and hemostatic biomarkers have been associated with worse outcomes in the general population with COVID, and may be also associated with worse outcomes in the cancer population.
In terms of thrombosis, VTE rates vary substantially by report, depending on whether patients were in the earlier part of the pandemic, the later part of the pandemic, pre vaccine, post vaccine, ambulatory setting, or hospital setting.
The most recent U.S. data that represented by a group in ASH in December, we found about - in a national dataset, found a 3% thromboembolism rate that's both venous and arterial, in a population that was different types of tumors including solid tumors and hematologic malignancies, and a mix of inpatients and outpatients.
Why COVID-19 leads to venous thromboembolism is displayed in this graph of mechanisms here. As you can see, many different factors contribute to the prothrombotic state in this setting, including complement activation, organ injury that leads to a very proinflammatory state which in turn can lead to increased factor VIII and a von Willebrand factor, endothelial cell dysfunction, platelet activation. And all of these things can lead to both fibrin formation and elevation on D-dimer.
In cancer patients specifically, certain factors have been found to be associated with increased COVID severity, including, as displayed here in this large registry data from the COVID and Cancer Registry, the absolute lymphocyte count, absolute neutrophil count, platelet counts, creatinine, a D dimer, LDH, and C-reactive protein.
Once cancer patients with acute COVID-19 get a blood clot, the treatment is similar as it is for treatment of acute VTE in cancer. For many years, this treatment used to be 6 months of low-molecular-weight heparin monotherapy, but in recent multiple randomized trials, as shown here on the slide, recurrent VTE appears to be a little bit less with direct oral anticoagulants, although this is associated with a slightly increased risk of major bleeding, seen in some but not all clinical trials of DOACs. And this increased risk of major bleeding appears to be primarily in the GI cancer population, as shown on the graph on the left. In non-GI cancer patients, you don't really see an increased association of major bleeding with the direct oral anticoagulants.
So the algorithm that’s followed in my practice is if you have a patient with COVID and cancer-associated VTE, if they don't have major GI, hepatic, or renal dysfunction, if they don't have any drug-drug interactions with drugs that they're on, if they don't have a high risk of bleeding, such as an unresected esophageal cancer, which is about most patients, about 70% of patients, then we would start with a direct oral anticoagulant, apixaban, rivaroxaban, or edoxaban. If they have one of those issues, then we would prefer to do the low-molecular-weight heparin.
Generally speaking, the duration of treatment should be at least 6 months, although it should be reassessed for both risk of bleeding and risk of recurrent VTE at 3 months and 6 months. At 6 months, we generally stop if the cancer is in remission and there's no active cancer therapy, or we continue if there is active cancer. This recommendation is concordant with guidelines from ASCO and ITAC, as shown here.
So to summarize, cancer patients are at risk for COVID-related complications given their immunocompromised status, the hypercoagulable state of cancer is enhanced during an acute COVID-19 infection. In terms of treatment, standard treatment guidelines for cancer-associated VTE should be followed. Anticoagulant approaches include Warfarin, low-molecular-weight heparins, and direct oral agents, and treatment should be continued for at least 6 months.
Thank you so much for your attention.
You have been listening to CME on ReachMD. This activity is jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc. and is part of our MinuteCME curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/CME. Thank you for listening.
This activity has been designed to meet the educational needs of the interprofessional team, including oncologists, hematologists, emergency medicine, hospitalists, internal medicine, nurse practitioners, physician assistants, nurses, and pharmacists, as well as other clinicians involved in the management of patients with cancer-associated venous thrombosis (CAT).
After participating in this educational activity, participants should be better able to:
- Understand recent evidence of the morbidity and mortality of VTE in patients with cancer and the importance of balancing the management of VTE while minimizing the risk of bleeding
- Apply real-world data and evidence-based guidelines to update algorithms for optimal integration of DOACs into clinical practice for the management of CAT
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Cihan Ay, MD, faculty for this educational event, received consulting fees from Bayer, BMS, Pfizer, and Sanofi.
Alok A. Khorana, MD, FACP, FASCO, faculty for this educational event, received consulting fees from Pfizer, Sanofi, BMS, Anthos, Bayer, Janssen, and Nektar; and received research funding from BMS and Celgene.
Jean M. Connors, MD, faculty for this educational event, received consulting fees from Abbott Laboratories, Alnylam Pharmaceuticals, Anthos Therapeutics, Bristol Myers Squibb, Pfizer, Roche, Sanofi S.A., and Werfen; and received research funding from CSL Behring.
The following planners/reviewers/managers have disclosed:
William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.
TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.
All the relevant financial relationships for these individuals have been mitigated.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
This activity is supported by an independent educational grant from Pfizer Inc.
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
This activity is FREE to all participants.
During the period 2/17/2023 through 2/17/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
- Read the learning objectives and faculty disclosures.
- Answer a pre-program question.
- View the program.
- Complete the post-test with a score of 100%.
- Complete activity evaluation.
- Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.